Evaluation of the Prognostic Role of Neutrophil-Lymphocyte Ratio, C-Reactive Protein-Albumin Ratio, and Platelet-Lymphocyte Ratio in Patients with the Co-Presentation of Coronary Artery Disease and COVID-19
Xiaoqun Xu,Xinyu Zhu,Hanxin Wang,Xiao Liu,Chao Yang,Libin Liu,Tielong Chen,Long Cai,Houyong Zhu
DOI: https://doi.org/10.2147/idr.s450318
2024-03-08
Infection and Drug Resistance
Abstract:Xiaoqun Xu, 1, &ast Xinyu Zhu, 2, &ast Hanxin Wang, 3 Xiao Liu, 3 Chao Yang, 3 Libin Liu, 1 Tielong Chen, 4 Long Cai, 1 Houyong Zhu 4 1 Centre of Laboratory Medicine, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, People's Republic of China; 2 Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China; 3 The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China; 4 Department of Cardiology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Houyong Zhu, Department of Cardiology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, No. 453 Stadium Road, Hangzhou, 310007, People's Republic of China, Email Long Cai, Department of Clinical Laboratory, Hangzhou Red Cross Hospital, NO. 208 East Huancheng Road, Hangzhou, 310003, People's Republic of China, Email Aim: The purpose of this study was to investigate the role of neutrophil-lymphocyte ratio (NLR), C-reactive protein-albumin ratio (CAR), and platelet-lymphocyte ratio (PLR) in the prognosis of patients with coronary artery disease (CAD) complicated with coronavirus disease 2019 (COVID-19). Methods: This study included 265 patients. A receiver operating characteristic (ROC) curve analysis was performed to preliminarily evaluate the predictive ability of NLR, CAR, and PLR for all-cause death. The primary outcome was all-cause death during hospitalization, while the secondary outcomes were cardiovascular death and respiratory failure death. The Cox proportional hazard model with adjusted covariates was used to analyze the cumulative risk of outcomes. We also conducted subgroup analyses based on the acute and chronic characteristics of CAD. Propensity score matching (PSM) was used to further evaluate the robustness of the primary outcome. Results: The ROC curve analysis results showed that the area under curve (AUC) values were 0.686 (95% CI 0.592– 0.781, P< 0.001) for NLR, 0.749 (95% CI 0.667– 0.832, P< 0.001) for CAR, and 0.571 (95% CI 0.455– 0.687, P=0.232) for PLR. The Cox proportional hazard model showed that trends in NLR and PLR did not affect the risk of all-cause death (P=0.096 and P=0.544 for trend, respectively), but a higher CAR level corresponded to a higher risk of all-cause death (P< 0.001 for trend). Similarly, The trends of NLR and PLR did not affect the risk of cardiovascular death and respiratory failure death, while a higher CAR level corresponded to a higher risk of cardiovascular death and respiratory failure death. The results of subgroup analyses and PSM were consistent with the total cohort. Conclusion: In patients with CAD complicated with COVID-19, a higher CAR level corresponded to a higher risk of all-cause death, cardiovascular death, and respiratory failure death, while trends in NLR and PLR did not. Keywords: coronary artery disease, coronavirus disease 2019, neutrophil-lymphocyte ratio, C-reactive protein-albumin ratio, platelet-lymphocyte ratio Recently, some randomized controlled trials have demonstrated that targeted inflammatory therapy improves the clinical outcomes for patients with atherosclerosis. The Colchicine Cardiovascular Outcomes Trial (COLCOT), 1 the second Low Dose Colchicine trial (LoDoCo-2), 2 and the Canakinumab Thrombosis Outcomes Study (CANTOS) 3 all found that anti-inflammatory treatment reduced the risk of cardiovascular adverse events in patients with coronary artery disease, with both COLCOT and CANTOS included patients showing a slight increase in baseline C-reactive protein (CRP). In contrast, the Cardiovascular Inflammation Reduction Trial (CIRT) 1 did not find any anti-inflammatory benefits of methotrexate for cardiovascular events. However, the baseline CRP of the patients it included was only 1.6mg/L. Therefore, although this study was neutral, it also increased interest in finding simple inflammatory biomarkers widely used in the clinical community. Adamstein et al 4 conducted a meta-analysis that included a series of large-scale clinical studies and found that neutrophil-lymphocyte ratio (NLR) effectively predicted the risk of cardiovascular adverse events. Some studies also found that CRP-albumin ratio (CAR) may be an important indicator for predicting cardiovascular risk. 5–9 Our previous studies 10,11 also confirmed that the combined indicator of CRP and albumin played a similar role in evaluating the prognosis of -Abstract Truncated-
pharmacology & pharmacy,infectious diseases